Introduction
============

The sequence of biopolymers such as DNA, RNA and proteins is elaborately controlled, and functional substituents at well-defined positions cooperatively play an essential role in their special and unique functions.[@cit1],[@cit2] Recently, sequence control of synthetic polymers has been drawing great interest towards creation of more advanced functions like those of natural polymers,[@cit3]--[@cit6] but the control remains a great challenge in polymer science.

Some concepts or methodologies for controlling the monomer sequence in synthetic polymers have been reported, including controlled radical polymerization,[@cit7]--[@cit11] ring-opening metathesis polymerization,[@cit12],[@cit13] DNA-templated synthesis,[@cit14],[@cit15] and iterative synthesis.[@cit16]--[@cit35] One-by-one iterative methods, which are generally carried out on a solid support, enable complete regulated monomer sequences for artificial peptides and DNA. Other notable examples include the method for the synthesis of triazene-based polymers,[@cit36] poly(alkoxyamine amide)s,[@cit37] oligothioetheramides,[@cit38]--[@cit40] and thiolactone aminolysis,[@cit41],[@cit42] and the multicomponent reaction.[@cit43]--[@cit45] Although solid-phase synthesis enables simple purification, solution-phase synthesis is desired due to its homogenous reaction kinetics and non-necessity for removal of the products from the solid support.[@cit46],[@cit47]

Peptoids (or poly-*N*-substituted glycines) are a class of biomimetic sequence-defined polymers that have found a wide range of biotechnological applications.[@cit48]--[@cit57] Peptoids are routinely synthesized using the solid-phase submonomer approach developed by Zuckermann *et al.*[@cit58] Up to now, several hundred commercially available amines have been applied to synthesize peptoids with a wide array of side chains.[@cit53],[@cit54] Although significant progress has been made in peptoids, developing a novel strategy towards the *de novo* synthesis of sequence-defined peptoids is still imperative. To ensure sufficient molecular diversity and complexity, it is highly desirable to synthesis backbone-variants of traditional α-peptoids, such as β-peptoids, which can expand the structural and functional repertoire of peptoids.[@cit52],[@cit54],[@cit59],[@cit60] However, submonomer synthesis similar to that used for α-peptoids was determined to be less efficient for β-peptoids.[@cit61] This challenge and the need for increased molecular diversity prompt us to develop a new approach to generate sequence-defined peptoids with broad structural diversity, both of the side chains and the backbones.

Herein, we describe a general route for the assembly of sequence-specific polymers through iterative Ugi reactions of amino acid building blocks ([Scheme 1](#sch1){ref-type="fig"}; see the ESI[†](#fn1){ref-type="fn"} for the detailed mechanism of the Ugi reaction). We hypothesized that amino acids, which supply the carboxylic acid and amino functions, could sequentially react with an aldehyde and an isocyanide to form a peptoid structure. In order to achieve scalability, we employed the efficient solution-phase synthesis, which theoretically allowed scalable reactions.[@cit23]--[@cit25] The Ugi reaction[@cit62]--[@cit67] was chosen as a coupling strategy due to its ability to introduce broad structural diversity *via* simply employing different amino acids or isocyanides in each step of the reaction.

![Synthesis strategy towards sequence-defined peptoids *via* amino acid building blocks and iterative Ugi reactions.](c8sc03415j-s1){#sch1}

Applying this approach, we performed the synthesis of sequence-defined peptoids with molar masses \>4 kDa on a ∼4 g scale. After this effective strategy, we further demonstrated that the variation in the overall hydrophobicity and lower critical solution temperature (LCST) behaviours of these precisely defined peptoids could be logically altered by variation of the sequence. Finally, we showed that these sequence-defined materials could be conjugated to DNA quantitatively, allowing the development of novel therapeutics in a facile way.

Results and discussion
======================

Amino acid building blocks
--------------------------

Our approach for achieving synthetic sequence control involves the synthesis of an amino acid-based building block. The building block framework includes a reactive amino group that can undergo Ugi reactions, and a *tert*-butyl ester protected carboxylic acid function that can undergo efficient deprotection. The amino acid building block can be synthesized from readily available amino acid starting materials (Fig. S1[†](#fn1){ref-type="fn"}). A unique feature of the amino acid platform is that a rich variety of amino acids enable the introduction of broad structural diversity into peptoid backbones. For this proof-of-concept study, we synthesized seven different amino acid building blocks **2a--g** ([Scheme 1](#sch1){ref-type="fig"}, Fig. S1 and S16--S54[†](#fn1){ref-type="fn"}).

A model short peptoid by iterative Ugi reactions
------------------------------------------------

To verify the feasibility of our approach, we initiated the synthesis of a short peptoid with glycine *tert*-butyl ester, **2a**. The amino functionality of **2a** was reacted in an Ugi reaction with, acetic acid **1** as the starting substrate and benzaldehyde, and *tert*-butyl isocyanide. The use of a 0.1-fold excess of aldehyde and isocyanide is necessary to push the reaction to quantitative transformation ([Fig. 1A and B](#fig1){ref-type="fig"}). In addition, purification of the resultant product was realized by flash chromatography on silica using ethyl acetate/dichloromethane/petroleum ether (1 : 1 : 1) as the eluent. The resultant material of the Ugi reaction bears a *tert*-butyl ester moiety, which can be used for another Ugi reaction after quantitative hydrolysis with trifluoroacetic acid (TFA) and simple workup by evaporation. The structure of the product after deprotection was confirmed by ^1^H NMR *via* the disappearance of the *tert*-butyl groups at 1.43 ppm (Fig. S2[†](#fn1){ref-type="fn"}) and by MALDI-TOF-MS (Fig. S3[†](#fn1){ref-type="fn"}). The isolated yield over the two steps was 90%. After this first round of the Ugi reaction and deprotection, we continued peptoid synthesis with another round of reactions. Again, both reactions proceeded smoothly as determined by ^1^H NMR and MALDI-TOF-MS ([Fig. 1C](#fig1){ref-type="fig"}, and S4[†](#fn1){ref-type="fn"}). Additionally, it should be noted that the obtained peptoid based on building block **2a** lacks chirality, due to the racemic characteristic of the Ugi product.[@cit68],[@cit69]

![(A) Synthesis of a model short peptoid by iterative Ugi reactions. (B) MALDI-TOF-MS spectrum of a 1-mer peptoid. (C) MALDI-TOF-MS spectrum of a 2-mer peptoid.](c8sc03415j-f1){#fig1}

Sequence-defined peptoids with side-chain diversity *via* iterative Ugi reactions
---------------------------------------------------------------------------------

Having demonstrated the efficient synthesis of the model short peptoid, we proceeded with the synthesis of 9-mer and 10-mer sequence polymers, peptoid **1** and peptoid **2** ([Fig. 2A and B](#fig2){ref-type="fig"}). Both polymers were synthesized with the same amino acid building block **2a** but have different side chain sequences. The synthesis of peptoid **1** and peptoid **2** was followed and confirmed at intermediate steps with MALDI-TOF-MS and SEC ([Fig. 2](#fig2){ref-type="fig"}, S5--S6 and S85--S86[†](#fn1){ref-type="fn"}). Further structural confirmation of both peptoids was obtained *via* MALDI-TOF-MS. The observed parent ions of the two peptoids were identical at 2252.4 Da and 2534.1 Da ([Fig. 2A and B](#fig2){ref-type="fig"}), and matched with the theoretical value of 2252.0 Da and 2533.9 Da, respectively. Furthermore, by the application of different aldehydes for the Ugi reaction, we could incorporate ten different pendant groups into the sequence-specific peptoid **3**, such as aliphatic, aromatic, and olefinic motifs ([Fig. 2C](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, S7 and S71[†](#fn1){ref-type="fn"}). We were pleased to note that the strategy for these sequence-defined peptoids is scalable, and multiple grams of linear peptoids were obtained. For instance, peptoid **3** (4.01 g) was produced in a 40% isolated yield over 19 steps as an off-white powder material (Fig. S8[†](#fn1){ref-type="fn"}), indicating the high efficiency of this chemistry. Therefore, using the above chemistry can afford sequence-defined polymers for valuable applications, facilitating the exploration of structure--property relationships accurately. Starting from bis--COOH--functionalized PEG, the sequence-defined block polymer (peptoid **4**) was synthesized using the above chemistry. The SEC curve ([Fig. 2D](#fig2){ref-type="fig"}) of the obtained peptoid **4** shifted to higher molecular weights (*M*~n~ ∼ 4.1 kDa), which was consistent with the successful formation of the desired symmetrical sequence-specific products.

![(A) Chemical structure and MALDI-TOF-MS spectrum of a 9-mer sequence polymer (peptoid **1**). (B) Chemical structure and MALDI-TOF-MS spectrum of a 10-mer sequence polymer (peptoid **2**). (C) Chemical structure and MALDI-TOF-MS spectrum of a 10-mer sequence polymer with ten different pendant groups (peptoid **3**). (D) Chemical structure and SEC traces of a sequence-defined block polymer (peptoid **4**).](c8sc03415j-f2){#fig2}

![SEC traces obtained after Ugi reactions in the synthesis of the sequence-defined peptoid **3** (in THF, 35 °C, polystyrene as a standard).](c8sc03415j-f3){#fig3}

To illustrate the versatility of this strategy, we synthesized a 5-mer α-peptoid **5** (Fig. S9[†](#fn1){ref-type="fn"}) consisting of [l]{.smallcaps}-alanine (**2b**) and benzyl-protected [l]{.smallcaps}-serine (**2c**) building blocks. SEC and MALDI-TOF-MS spectra revealed its structural integrity. The corresponding peptoid **6** (Fig. S9 and S75[†](#fn1){ref-type="fn"}) with pendant hydroxyl groups was recovered by hydrolysis of *tert*-butyl ester followed by removal of the benzyl protecting group. The presence of hydroxyl groups in its side chains would enhance the hydrophilicity of the resultant peptoids, facilitating its biomedical applications.

Sequence-defined peptoids with backbone diversity *via* iterative Ugi reactions
-------------------------------------------------------------------------------

Faced with the ever-present challenge of β-peptoid preparation using the submonomer method,[@cit54] we further synthesized a 10-mer β-peptoid **7** with β-alanine *tert*-butyl ester **2d** as the building block, according to the aforementioned procedure ([Fig. 4A](#fig4){ref-type="fig"}, S76 and S87[†](#fn1){ref-type="fn"}). Importantly, the chemistry for β-peptoids is high efficient, and the isolated yield in each cycle over two successive steps (that is the Ugi reaction and deprotection) was ∼85%.

![(A) Synthetic route and MALDI-TOF-MS spectrum of 10-mer β-peptoid **7** obtained by iterative Ugi reactions using β-alanine *tert*-butyl ester as the building block. (B) Chemical structure and MALDI-TOF-MS spectrum of a 5-mer peptoid consisting of all five amino acid building blocks (peptoid **8**).](c8sc03415j-f4){#fig4}

The versatility and robustness of the above chemistry for building sequence-defined polymers were further demonstrated by constructing backbone-variants of traditional α-peptoids. We synthesized a 5-mer peptoid ([Fig. 4B](#fig4){ref-type="fig"}, S77 and S88[†](#fn1){ref-type="fn"}) consisting of all five amino acid building blocks. The resulting peptoid **8** was characterized by the MALDI-TOF-MS spectrum, and the doubly charged \[M -- O^*t*^Bu\]^+^, and \[M -- O^*t*^Bu -- Ac\]^+^ ions were clearly observed. Thus, the iterative Ugi reaction combined with amino acid building blocks is indeed a very powerful new approach towards sequence-defined peptoids with backbone diversity.

Effect of the sequence structure of peptoids on materials properties
--------------------------------------------------------------------

The above chemistry can afford an array of sequence-defined polymers for accurately exploring the structure--property relationship. In particular, the study of the properties of polymers with similar chemical structures but different sequence structures is a fundamental topic in the polymer science area. For this purpose, we employed the *tert*-butyl isocyanide and oligo-ethylene-glycol isocyanide to make 12-mer peptoids **9--12** containing hydrophobic and hydrophilic side chains ([Fig. 5A and B](#fig5){ref-type="fig"}, S10--S12, and S78--S81[†](#fn1){ref-type="fn"}). SEC measurements demonstrate the successful synthesis of the desired peptoids by the shifting towards higher molecular weights after each step (Fig. S89--S92[†](#fn1){ref-type="fn"}). Each of these peptoids differs in the placement fashion of the hydrophobic and hydrophilic units, which were grouped into a block size of one (peptoid **12**), two (peptoid **11**), three (peptoid **10**), and six (peptoid **9**). The resultant peptoids were soluble in cold water. The lower critical solution temperature (LCST) behaviours of these peptoids were investigated. As shown in [Fig. 5C](#fig5){ref-type="fig"}, a gradual increase in LCST was detected as the block size decreased from six in peptoid **9** to one in peptoid **12**, demonstrating a gradual increase in the overall hydrophilicity. This may be due to the fact that the more water-soluble peptoid **12** may adopt a structure in which the hydrophilic OEG moieties provide better shielding of the hydrophobic portion from water.

![(A) Illustration of the side-chain sequence-regulated peptoids **9--12** synthesized by iterative Ugi reactions. (B) MALDI-TOF-MS spectrum of 12-mer peptoid **12**. (C) Temperature dependence of transmittance for the aqueous solutions (2 mg mL^--1^) of sequence-regulated peptoids **9--12** (500 nm, heating at a rate of 1 °C min^--1^).](c8sc03415j-f5){#fig5}

Furthermore, to elucidate the backbone monomer sequence on the polymer properties, we applied the glycine *tert*-butyl ester **2a** and oligo-ethylene-glycol based amino acid *tert*-butyl ester **2h** (Fig. S1 and S55--S61[†](#fn1){ref-type="fn"}) as building blocks to make a series of main-chain sequence-regulated peptoids **13--15** ([Fig. 6](#fig6){ref-type="fig"}). Peptoids with ABB and AABBB sequence-regulated backbone structures, and peptoids with a block sequence in the backbone were verified by MALDI-TOF-MS and SEC measurements ([Fig. 6B](#fig6){ref-type="fig"}, S13--S14, and S93--S95[†](#fn1){ref-type="fn"}). The solubility of these peptoids was then assessed in the mixed solvents of EtOH and H~2~O at different temperatures *via* determining the light transmittance of the peptoid solutions. As shown in [Fig. 6C](#fig6){ref-type="fig"}, the peptoids with the same composition but different monomer sequences in the backbones, *i.e.*, peptoid **13**, peptoid **14** and peptoid **15**, showed different solubilities; the peptoid with an ABB alternating sequence in the backbone (peptoid **15**) was more soluble than the others: it became turbid at *T*~c~ = 45 °C (*T*~c~: cloud point), whereas its block counterpart (peptoid **13**) did so at a higher temperature, *T*~c~ = 53 °C. These experiments again suggested that not only the side-chain sequences but also the backbone sequences were important for determining the solubility of the peptoids and that the solubility could be gradually adjusted by both backbone and side-chain monomer sequences. Actually, the interaction preference between the polymer and solvent might be changed depending on the placement fashion of monomer units.

![(A) Illustration of the backbone sequence-regulated peptoids **13--15** obtained by iterative Ugi reactions using glycine *tert*-butyl ester and oligo-ethylene-glycol based amino acid *tert*-butyl ester as building blocks. (B) MALDI-TOF-MS spectrum of 10-mer peptoid **13**. (C) Transmittance of the backbone sequence-regulated peptoids **13--15** at varying temperatures in EtOH/H~2~O (2/3) (2 mg mL^--1^, 500 nm, cooling at a rate of 2 °C min^--1^).](c8sc03415j-f6){#fig6}

Bioconjugation of peptoids
--------------------------

One possible application of the resultant sequence-specific peptoids may be in nucleic acid delivery. In addition, research on the combination of synthetic materials and biologics through bioconjugation has been the subject of increased study because this integration enables the development of novel therapeutics.[@cit19],[@cit70] Therefore, we evaluated whether our peptoids could be coupled to DNA for biomedical applications. By applying the same Ugi reaction and 3-azidopropan-1-amine as a component, we attached an azide functionality to a peptoid ([Fig. 7A](#fig7){ref-type="fig"} and S15[†](#fn1){ref-type="fn"}). The azide-modified peptoid **16** was coupled to DNA with a dibenzocyclooctyne (DBCO) group under ambient conditions without catalysts with acetonitrile and PBS as solvents. DBCO-DNA specifically conjugated to peptoid **16** based on gel electrophoresis shifts, and a 24 h reaction with DNA: peptoid molar ratio = 1 was found to be efficient based on the disappearance of the unconjugated DNA gel band ([Fig. 7B](#fig7){ref-type="fig"}). Further verification of conjugation was obtained *via* MALDI-TOF-MS ([Fig. 7C](#fig7){ref-type="fig"}).

![(A) Conjugation of sequence-defined peptoid **16** to DNA (DNA: peptoid molar ratio = 1, 24 h reaction in CH~3~CN/PBS). (B) Gel-electrophoresis result for the peptoid-DNA conjugation reaction. (C) MALDI-TOF-MS analysis of DNA conjugates.](c8sc03415j-f7){#fig7}

Conclusions
===========

In summary, we have described herein the development of amino acid building blocks coupled with iterative Ugi reactions for the efficient and multigram-scale assembly of sequence-defined peptoids. This efficient chemistry provides much feasibility for structural diversity, synthetically varying and sequencing both the side chains and the backbones. Activating agents were unnecessary, rendering this strategy advantageous over other stepwise methods, such as the traditional peptide or peptoid synthesis. We further demonstrated that the alteration in the overall hydrophobicity and LCST behaviours of these precisely defined peptoids could be accordingly changed by variation of the sequence. Regulation of sequence specific hydrophobic aggregation within a polymer is a significant result. We also showed that these materials could be conjugated to biomacromolecules, allowing the development of novel therapeutics. We anticipate that this versatile strategy may afford new peptoids for application in therapeutics and as supramolecular foldamers or simple protein mimics for the investigation of advanced self-assembly driven by hydrophobic or other supramolecular interactions.
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